Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare is attractive because its core Personal Care franchise is delivering solid organic momentum, with 1Q26 same-store revenue up 6.5% and segment revenue rising 8.8% to $281.1 million, supported by higher billable hours, better utilization, and improving rates. The company also appears well positioned to accelerate growth through acquisitions, given the sharp drop in M&A spend to $32 million in 2025, a constructive 2026 pipeline, $103 million in cash versus $94 million of debt at the end of Q1, and expected 2026 EBITDA and FCF of $196 million and $120 million. Further support comes from favorable regulatory and reimbursement trends in personal care and hospice, plus 1Q26 adjusted EBITDA of $44.5 million with a 12.2% margin that demonstrates resilient profitability.

Addus HomeCare is viewed negatively because its core Personal Care business faces meaningful policy and reimbursement risk, including potential Medicaid funding reforms, the 80/20 Medicaid Access Rule, and state-level wage or rate changes that could compress margins. More than 20% of revenue comes from Illinois CCP, making any program changes disproportionately harmful, while hospice and home health are also exposed to Medicare reimbursement pressure and labor constraints that may limit growth. Although 1Q26 revenue rose 7.7% year over year to $363.6M and EBITDA reached $44.5M, hospice revenue missed expectations, home health revenue fell 6.6% organically, and Gentiva integration adds further execution risk.